Last reviewed · How we verify
ADG126-anti PD1
At a glance
| Generic name | ADG126-anti PD1 |
|---|---|
| Sponsor | Adagene Inc |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer (PHASE1)
- ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
- ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADG126-anti PD1 CI brief — competitive landscape report
- ADG126-anti PD1 updates RSS · CI watch RSS
- Adagene Inc portfolio CI